Puridify, a spin-out company that was created by UCL Biochemical Engineering graduates and formed from research by Professor Dan Bracewell, has won the category “Partnerships that have proven to result in significant benefits toward accelerating drug development” for their work with GlaxoSmithKline. They were also a finalist in the category “Best Technology Application – Downstream: User or supplier that has been able to demonstrate reduction in downstream processing steps, time, and cost” for their product FibroSelect.
You can see the full list of winners here: http://www.newson6.com/story/33341890/bioprocess-international-announces-winners-of-the-2016-bioprocess-international-awards
The FibroSelect technology seeks to dramatically increase productivity of the purification operations in bioprocessing. In doing so this allows the replacement of large chromatography columns with far smaller FibroSelect units. This scale reduction and transfer into a pre-loaded format makes it economical to operate the FibroSelect technology in a “single-use” manner. In an industrial development and production setting this leads to significant advantages in terms of process development, facility operation, and overall responsiveness of manufacturing to external requirements.
Oliver Hardick, CEO of Puridify commented: “Being nominated for these two awards, which puts Puridify alongside the likes of Pall Corporation and Sanofi-Genzyme, was an incredible honour and testament to the hard work and excellence of our R&D team. Our platform continues to demonstrate enormous relevance and value to the process development community, and industrial support from leading biopharmaceutical companies across Europe and the USA is helping us move towards commercial manufacture of the FibroSelect technology. The willingness to engage gives us confidence in the industry’s readiness to adopt novel technologies that make significant productivity gains and reduce process development times, which will ultimately deliver benefits to patients.”
